H. Lundbeck A/S (LON: 0ABR)

Market Cap	4.38B
Revenue (ttm)	2.39B
Net Income (ttm)	299.84M
Shares Out	n/a
EPS (ttm)	0.30
PE Ratio	14.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Mar 21, 2024

Volume	508
Average Volume	973
Open	32.40
Previous Close	32.20
Day's Range	32.40 - 32.75
52-Week Range	3.06 - 4.63
Beta	n/a
RSI	42.33
Earnings Date	Feb 5, 2025

About H. Lundbeck

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat M...

• Industry: Pharmaceutical Preparations
• Founded: 1915
• Employees: 5,681
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ABR

Financial Performance

In 2023, H. Lundbeck's revenue was 19.91 billion, an increase of 9.13% compared to the previous year's 18.25 billion. Earnings were 2.29 billion, an increase of 19.52%.

Financial numbers in DKK